CBE 201
Alternative Names: CBE-201Latest Information Update: 26 Feb 2024
At a glance
- Originator Cell BioEngines
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Head and neck cancer; Lung cancer
Most Recent Events
- 11 Jan 2024 CBE 201 is available for licensing as of 11 Jan 2024. https://cellbioengines.com/our-pipeline
- 10 Jan 2024 Preclinical trials in Colorectal cancer in USA (Parenteral) (Cell BioEngines pipeline, January 2024)
- 10 Jan 2024 Preclinical trials in Head and neck cancer in USA (Parenteral) (Cell BioEngines pipeline, January 2024)